Influence of chenodeoxycholic acid on serum triglycerides in patients with primary hypertriglyceridemia.
Administration of chenodeoxycholic acid (CDCA) to patients with primary hypertriglyceridemia caused the diminution of serum triglyceride concentrations of 54.31% and 46.04% at dosages of 500 mg/day and of 250 mg/day, respectively. Results after 1 month of treatment with 250 mg/day are not statistically different from those obtained with 500 mg/day. Administration of CDCA did not change the serum cholesterol, SGOT, SGPT, total bilirubin, gammaGT or alkaline phosphatase levels.
D000328:Adult; D002635:Chenodeoxycholic Acid / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013997:Time Factors; D014280:Triglycerides / Q000097:blood*
D010919:Placebos; D014280:Triglycerides; D002635:Chenodeoxycholic Acid